BNET Industries
- Private
- US
Dow Jones Description
Invitrogen is committed to being the leading provider of novel fluorescent reagents and detection solutions that advance scientific and biomedical research worldwide. Supplying superior Molecular Probes products and services, together with striving for customer and employee satisfaction, will be the driving forces of our organization.
Senior Vice PresidentBen Bulkley
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
invitrogen corp. - All News and Analysis
Invitrogen Corp. Q3 2008 Earnings Conference Call Transcript
Question-and-Answer SessionThank you. [Operator Instructions]. Your first question comes from the line of Tycho Peterson with JP Morgan. Please proceed with your question. Tycho W. Peterson - JP Morgan Hi good afternoon. Wondering maybe, Greg, if you can just comment a little bit more on the VisiGen acquisition, where...
Applied Biosystems Inc. First Quarter Fiscal 2009 Financial Results and Conference Call Scheduled for October 22, 2008
Company Reiterates Outlook for the Quarter NORWALK, Conn. -- Applied Biosystems Inc. (NYSE:ABI) announced today that it will issue fiscal 2009 first quarter financial results on Wednesday, October 22, 2008. Results are scheduled for release before the opening of trading on the New York Stock Exchange. Applied Biosystems...
Invitrogen Joins EPA's Climate Leaders Program
CARLSBAD, Calif. -- As a part of its continued commitment to environmental sustainability, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced its participation in the U.S. Environmental Protection Agency's (EPA's) Climate Leaders program. By participating in Climate Leaders, Invitrogen has pledged...
Invitrogen Files Merger Notification With European Commission
CARLSBAD, Calif. -- Invitrogen Corporation (NASDAQ:IVGN) today announced that it has filed the necessary formal notification to the European Commission with respect to its pending acquisition of Applied Biosystems Inc. (NYSE:ABI). Under European Commission rules, the Commission has 25 business days following the date of notification to respond to the...
San Diego public stocks
Index Watch Net Index...
Applied Biosystems Announces Internet Availability of Its 2008 Annual Report on Form 10-K
NORWALK, Conn. -- Applied Biosystems Inc. (NYSE: ABI) today announced the Internet availability of its 2008 Annual Report on Form 10-K. The Annual Report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and may be accessed through the Company's investor relations website at http://ir.appliedbiosystems.com. Applied...
Applied Biosystems Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger With Invitrogen Corporation
NORWALK, Conn. -- Applied Biosystems Inc. (NYSE:ABI) today announced it has set the date for a special meeting of its shareholders to consider the proposed merger with Invitrogen Corporation. The special meeting of shareholders will be held on October 16, 2008, at 9:30 a.m. EDT. Applied Biosystems shareholders of record...
All four IBO indexes defy market turbulence
Disappointing economic news continued to weigh on the US markets this month. On July 31, the US reported second-quarter economic growth of 1.9%, compared to economists' expectations of 2.3%. The US also lowered its GDP estimates for the first quarter of this year and the fourth quarter of 2007 to...
Invitrogen Corp. Q2 2008 Earnings Call Transcript
Question-and-Answer Session[Operator Instructions]. And the first question comes from the line of Tycho Peterson from JPMorgan. You may proceed. Tycho W. Peterson - JPMorgan Hi, good morning. Thanks for taking the call. Gregory T. Lucier - Chairman and Chief Executive Officer Good morning. David F. Hoffmeister - Chief Financial...
Half-year litigation review: two trial dates approach
In the first of IBO's twice yearly report on new litigation among analytical instrument and laboratory product providers, we take a look at new patent infringement cases, as well as update the latest developments in other cases. Two cases are scheduled to come to trial in the next few months,...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Ben Bulkley | Senior Vice President |
| David U'Prichard | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald W Grimm | Board Member |
| Raymond V. Dittamore | Board of Directors |
| W. Ann Reynolds PhD | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Invitrogen Corporation | Senior Vice President | Current |
| UCSD-CONNECT | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Venture Partner | Current |
| Red Abbey, LLC | Senior Advisor and Venture Partner | Current |
| University of Glasgow | Honorary Professor | Current |
| Red Abbey, LLC | Advisor | Current |
| Northwestern University | Associate Professor | Current |
| Glasgow University | Honorary Professor | Current |
| Genematrix, Inc. | Board Director | Current |
| Exsar Corporation | Board Director | Current |
| Guilford Pharmaceuticals, Inc. | Director | Current |
| Invitrogen Corporation | Director | Current |
| Cyclacel Limited | Board of Directors | Current |
| GlaxoSmithKline Plc | President | Former |
| SmithKline Beecham Corporation | President of Research and Development | Former |
| Druid Consulting | President | Former |
| Apax Partners Ltd. | Venture Partner | Former |
| Northwestern University School of Medicine | Associate Professor of Pharmacology and Neurobiology | Former |
| Biotechnology Industry Organization | member | Former |
| GlaxoSmithKline Plc | Chairman of Research and Development | Former |
| SmithKline Beecham Corporation | Chairman of R&D | Former |
| Biotechnology Industry Organization | Board Member | Former |
| University of Kansas | Ph.D. in Pharmacology | Former |
| University of Kansas | MS | Former |
| University of Glasgow | B.Sc. in Pharmacology | Former |
| Organization | Position | Status |
|---|---|---|
| Oligoperfect | Founder, Chairman and President, Strategic Design | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Founder, Chairman and President, Strategic Design | Current |
| Industry Ventures | Founder, Chairman and President, Strategic Design | Current |
| Emiliem, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Ionsource, LLC | Founder, Chairman and President, Strategic Design | Current |
| Bioreliance Corporation | Founder, Chairman and President | Current |
| Hamilton BioVentures | President | Current |
| Strategic Design | President | Current |
| Biolayer Corporation Limited | Founder, Chairman and President, Strategic Design | Current |
| Microseq | Founder, Chairman and President, Strategic Design | Current |
| IDEXX Laboratories, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Seqanswers | Founder, Chairman and President, Strategic Design | Current |
| Molecular Probes | Founder, Chairman and President, Strategic Design | Current |
| Aegis Therapeutics, LLC | Executive Chairman | Current |
| Strategic Design | Chairman | Current |
| Cellzdirect, Inc. | Board of Directors | Current |
| San Diego Regional Chamber of Commerce | Vice Chair | Current |
| High Throughput Genomics, Inc. | Board of Directors | Current |
| Scripps Clinic | Board Member | Current |
| Multiple Peptide Systems Inc | Board of Directors | Current |
| Angstrom Pharmaceuticals, Inc. | Board of Directors | Current |
| Invitrogen Corporation | Board Member | Current |
| University of Pittsburgh School of Pharmacy | Board Member | Current |
| Intec Telecommunications | Board Member | Current |
| Hamilton BioVentures | Director | Current |
| Dura Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Hybritech, Inc. | CEO | Former |
| Biosource International, Inc. | Founder, Chairman and President, Strategic Design | Former |
| Hybritech, Inc. | President | Former |
| Copenhagen Capacity | Managing Director | Former |
| Eli Lilly and Company | Director of Pharmaceutical Market Research | Former |
| Hybritech, Inc. | Director of West Coast Pharmaceutical Sales | Former |
| Eli Lilly and Company | management positions | Former |
| U.S. Army | Officer | Former |
| Cadence Pharmaceuticals, Inc. | Former | |
| Xcel Pharmaceuticals, Inc. | Former | |
| Verus Pharmaceuticals | Former | |
| Hybritech | Chairman | Former |
| Biovail Corporation | Chairman | Former |
| Hybritech, Inc. | Chairman | Former |
| Roundtable Inc. | Board of Directors | Former |
| Pharmaceutical Market Research | Director | Former |
| California Healthcare Institute, Inc. | Board of Directors | Former |
| Somaxon Pharmaceuticals, Inc. | Board of Directors | Former |
| Bioreliance Corporation | Director | Former |
| Baldwin-Wallace College | Master's Degree In Business Administration | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | M.B.A. | Former |
| University of Pittsburgh | M.B.A. | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | B.S. In Pharmacy | Former |
| University of Pittsburgh | B.S. In Pharmacy | Former |
Raymond V. Dittamore has served as a Director of the Company since December 2002. Mr. Dittamore is a retired audit partner of Ernst & Young LLP, an international accounting firm. Mr. Dittamore retired in 2001 after 35 years of service with that firm, including 14 years as the managing partner of the firms San Diego office. Mr. Dittamore is also a director of Invitrogen Corporation, Gen-Probe Incorporated, and Digirad Corporation. Mr. Dittamore received a B.S. degree from San Diego State University.
| Organization | Position | Status |
|---|---|---|
| QUALCOMM Incorporated | Board of Directors | Current |
| Molecular Probes | Director | Current |
| Invitrogen Corporation | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Biolayer Corporation Limited | Director | Current |
| Ionsource, LLC | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Applied Molecular Evolution, Inc. | Director | Current |
| Ernst & Young | partner | Former |
| Ernst & Young | collaborative editor | Former |
| Digirad Corporation | Board of Directors | Former |
| San Diego State University | B.S. | Former |
| QUALCOMM Incorporated | member | Former |
| Organization | Position | Status |
|---|---|---|
| Invitrogen Corporation | Board of Directors | Current |
| Abms Member | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Owens Corning | Board of Directors | Current |
| Business-Higher Education Forum | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Abbott Laboratories | Board of Directors | Current |
| Humana Inc. | Board of Directors | Current |
| News Gazette Inc. | Director | Current |
| KMG America Corporation | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Maytag Corporation | Board of Directors | Current |
| Ionsource, LLC | Board of Directors | Current |
| The University of Alabama at Birmingham | President | Former |
| University of Illinois College of Medicine | Research Professor | Former |
| University of Illinois | Professor | Former |
| Emporia State University | M.S. | Former |
| Emporia State University | Bachelors Degree In Biology | Former |
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
